[Basic and clinical studies of cefminox in obstetrics and gynecology].
The study was done to evaluate the usefulness of cefminox (CMNX, MT-141) injection for the treatment of infections in the field of obstetrics and gynecology. Fundamental and clinical studies were made and following results were obtained. When 1 g of CMNX was administered by intravenous single shot, the maximum concentrations in various tissues of female genital organs were as follows: 34.98 micrograms/g in oviduct at 1 hour 10 minutes after the single shot, and 37.11, 28.01, 26.84, 30.01 and 40.06 micrograms/g in ovary, endometrium, myometrium, cervix uteri and portio, respectively, after 1 hour 20 minutes. In the clinical studies, CMNX was given to 13 cases with female genital organ infections and others. As for the clinical effects, responses were excellent in 1 case, good in 12 cases among 13 cases in total. The efficacy rate was 100%. As for the clinical effects on causative bacteria, the efficacy rates were 100% (3/3) for single infections due to Gram-negative bacteria, 100% (8/8) for mixed infection cases. Side effects were not observed. CMNX showed a satisfactory clinical efficacy and a potent bacteriological effect in treatment of the infection in the field of obstetrics and gynecology, and it has been concluded that CMNX will be a useful addition to the antibiotics for the therapy of these infections.
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D002513:Cephamycins / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D002923:Cilia / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D007889:Leiomyoma / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism; D010053:Ovary / Q000378:metabolism; D014594:Uterine Neoplasms / Q000378:metabolism
D002513:Cephamycins; C046079:cefminox